Shenzhen - Delayed Quote • CNY Jiangxi Sanxin Medtec Co.,Ltd. (300453.SZ) Follow Add holdings 8.19 -0.20 (-2.38%) At close: 3:04:19 PM GMT+8 Related News Unity upgrade, UiPath earnings, Regeneron drug trial results Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including Unity Software's (U) upgrade to Buy from Jefferies analysts, UiPath (PATH) beating its earnings estimates, and Regeneron Pharmaceuticals (REGN) taking a stock hit on its mixed drug trial results for an experimental treatment to a condition referred to as smoker's lung. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. Gap tariff hit, Ulta forecast, Dell outlook: Trending Tickers Gap (GAP) stock plummets as the projected cost of tariffs weighs on the retailer's outlook. Ulta (ULTA) lifts its annual profit outlook, highlighting resilient beauty demand. Dell Technologies (DELL) raises its full-year outlook, citing artificial intelligence (AI)–driven demand. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Gap's Q1 earnings beat overshadowed by up to $300M tariff hit Gap (GAP) stock is plunging in after-hours trading as investors focus on the retailer's expected tariff hit rather than its first quarter earnings beat. The company's revenue was $3.46 billion, compared to the $3.42 billion expected, while earnings per share (EPS) came in at $0.51, better than the $0.45 analysts estimated. The retailer said it expects the tariff impact to cost up to $150 million in its 2025 operating income and $250–300 million in its gross estimated incremental cost. Gap maintained its full-year outlook but noted that this guidance doesn't reflect potential tariff impacts. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Dell blows past Q2 guidance expectations. Stock gets lift. Dell Technologies (DELL) posted mixed first quarter results on Thursday, releasing net revenue figures of $23.38 billion (vs. estimates of $23.15 billion) while adjusted earnings came out to $1.55 per share (shy of estimates for $1.69). Julie Hyman and Josh Lipton dive into Dell's report as the computer company's second quarter revenue forecasts blew past Wall Street consensus and where it stands amid AI server demands. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Why Palantir Stock is Jumping Today Palantir Soars on News It's Central to Administration's Data Overhaul Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More U.S. equities were lower at midday on concerns about where the U.S.-China trade war is heading. RBC Reaffirms Outperform on Regeneron (REGN) Ahead of Key COPD Drug Results Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on May 29. The rating comes as Regeneron awaits the findings of a phase III study on the medication candidate itepekimab, which is intended to treat chronic obstructive pulmonary disease (COPD). Based on a thorough analysis of preclinical […] Marvell Stock Slides. Why It Could Be the Cheap AI Chip Play. The company’s earnings didn’t dispel concerns it might lose out on designing Amazon’s Trainium AI chips. Still, analysts are upbeat. Marvell Technology Posts In-Line Q1 Results Driven by AI Data Center Strength, Morgan Stanley Says Marvell Technology's (MRVL) in-line Q1 results were driven by strength from its artificial intellige Dell Technologies Could Issue Positive EPS Revisions in H2, Morgan Stanley Says Dell Technologies (DELL) could issue positive earnings per share revisions in the second half of the Why Costco Stock Just Popped How much is too much to pay for Costco stock? Investors disagree. Ulta Beauty Outlook Leaves Room for Upside on Strong Execution, UBS Says Ulta Beauty (ULTA) has "plenty" of room for upside following its solid fiscal Q1 results, UBS Securi Elastic Likely to Overcome Potential Downside Risks, Extending Momentum After Better-Than-Expected Q4 Results, Oppenheimer Says Elastic (ESTC) exceeded Wall Street forecasts with its fiscal Q4 results but the better-than-expecte Market Chatter: Palantir Selected by Trump to Compile Data on Americans The Trump administration has turned to Palantir Technologies (PLTR) to put the technological buildin Marvell Shares Tumble Amid Concerns Over Next-Gen AI Ramp Marvell Shares Slide Amid Mixed Analyst Notes UiPath Tops Q1, Raises FY26 Guidance UiPath sees $1.55 billion revenue versus $1.52 billion consensus as ARR hits $1.69 billion COPD Drug Developed by Regeneron, Sanofi Fails Key Test A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial. Nvidia and Dell Team Up to Build Department of Energy Supercomputer Dell's Liquid-Cooled Leap: Nvidia Partnership Fuels DOE's AI Push DELL Q1 Earnings Miss Estimates, Revenues Up Y/Y, Shares Fall Dell Technologies' first-quarter fiscal 2026 results reflect strong AI-driven growth and an expanding backlog. These Stocks Are Moving the Most Today: Nvidia, Dell, Ulta, Gap, Marvell, American Eagle, and More Nvidia falls after rallying Thursday, Marvell’s latest earnings fail to impress Wall Street, and Gap and American Eagle contend with tariff uncertainty. Performance Overview Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) Return 300453.SZ SSE Composite Index (000001.SS) YTD +12.55% -0.13% 1-Year +17.71% +8.27% 3-Year +25.85% +6.30%